Establishment Labs (NASDAQ:ESTA) Stock Price Up 6.3% – Still a Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price shot up 6.3% on Thursday . The stock traded as high as $39.70 and last traded at $39.54. 238,138 shares traded hands during trading, a decline of 50% from the average session volume of 476,090 shares. The stock had previously closed at $37.18.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ESTA. Wall Street Zen lowered Establishment Labs from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. BTIG Research began coverage on Establishment Labs in a report on Friday, May 16th. They set a “buy” rating and a $62.00 price objective on the stock. Needham & Company LLC raised Establishment Labs from a “hold” rating to a “buy” rating and set a $48.00 price objective on the stock in a report on Wednesday, May 14th. Finally, Stephens reissued an “overweight” rating and set a $52.00 price objective on shares of Establishment Labs in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $52.40.

Establishment Labs Trading Down 0.1%

The company has a 50-day simple moving average of $33.51 and a 200-day simple moving average of $37.55. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The stock has a market cap of $1.10 billion, a P/E ratio of -14.73 and a beta of 0.74.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. During the same quarter in the previous year, the company posted ($0.58) EPS. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Establishment Labs

Institutional investors and hedge funds have recently made changes to their positions in the company. Quarry LP bought a new stake in shares of Establishment Labs during the fourth quarter worth $27,000. ANTIPODES PARTNERS Ltd bought a new stake in shares of Establishment Labs during the first quarter worth $81,000. KLP Kapitalforvaltning AS bought a new stake in shares of Establishment Labs during the fourth quarter worth $161,000. Elevation Point Wealth Partners LLC bought a new stake in shares of Establishment Labs during the first quarter worth $207,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Establishment Labs during the first quarter worth $234,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.